Tag
This review explores how paramagnetic rim lesions (PRLs), as markers of chronic active demyelination, serve as powerful predictors for clinical Multiple Sclerosis conversion in individuals with radiologically isolated syndrome.
**Refining Content Structure** I’m now deeply immersed in the content. I’ve drafted the introduction, designed to capture attention and set the scene. I am expanding on the key findings, including correlations, and the clinical
This study demonstrates that while MS genetic risk factors are largely shared across ancestral groups, their predictive power and population-level impact vary significantly between European, South Asian, and African populations.
Five-year data from the ULTIMATE I and II open-label extension demonstrate that ublituximab maintains exceptionally low relapse rates and slows disability progression in relapsing multiple sclerosis, emphasizing the clinical superiority of
The Phase 2 FENopta trial demonstrates that fenebrutinib, a highly selective, reversible BTK inhibitor, significantly reduces MRI disease activity by 69% in relapsing multiple sclerosis while maintaining a favorable safety profile over 48 w
A large French registry study shows that how disease-modifying therapies (DMTs) are managed during pregnancy meaningfully affects relapse rates in relapsing‑onset MS; prolonged natalizumab interruption and fingolimod use carry the highest r
In a large phase 3 trial, simvastatin 80 mg daily did not reduce disability progression in secondary progressive multiple sclerosis, challenging prior phase 2 results and underscoring the complexity of neurodegeneration in SPMS.
A comprehensive analysis reveals that menopause does not significantly alter the risk of disability progression in women with relapse-onset multiple sclerosis, underscoring the complexity of reproductive aging’s role in disease trajec
This study evaluates how pregnancy affects relapse rates and long-term disability in women with moderate to severe multiple sclerosis (MS), showing pregnancy reduces relapse during gestation without worsening long-term disability progressio
Higher baseline serum alpha-linolenic acid levels predict reduced multiple sclerosis activity, relapses, and disability progression up to 11 years post clinical onset in a large prospective study.
Managing disease-modifying therapies (DMTs) during pregnancy in women with multiple sclerosis significantly affects relapse risk, with anti-CD20 strategies demonstrating superior protection compared to other approaches.
Fenebrutinib, a selective BTK inhibitor, demonstrated significant reduction in new brain lesions and low relapse rates in relapsing multiple sclerosis, with a favorable safety profile in the FENopta phase 2 trial.
Tolebrutinib reduced disability progression in nonrelapsing secondary progressive MS but did not surpass teriflunomide in reducing relapse rates in relapsing MS. Safety signals include elevated liver enzymes and minor bleeding risks.
